tkadm30 Posted January 28, 2017 Posted January 28, 2017 Why is aripiprazole (Abilify) considered a third-generation atypical antipsychotic?
jbn22 Posted February 8, 2017 Posted February 8, 2017 Well, first off, Aripiprazole defines a structural class distinct from FGAs (Butyrophenones, Thioxanthenes, Benzamides, Phenothiazines, etc.) and SGAs (Dibenzepines, Benzisoxalderivatives). Unlike FGAs and SGAs, Aripiprazole is a partial agonist instead of a full antagonist. This means its effect is inherently limited (ceiling) and it has a very good profile of unwanted sideeffects (no net weight gain, good function in terms of negative symptoms, etc.). The partial agonism also leads to aripiprazole being able to (when added to the regimen) actually reduce EPS in patients receiving high-dosed FGAs because it competitively inhibits FGA function. The term "third generation" antipsychotic is something I haven't heard of yet. But Aripiprazole is so much unlike the other antipsychotics due to its partial agonism that I guess you could call it that.
tkadm30 Posted February 8, 2017 Author Posted February 8, 2017 OK. Thanks for this information, jbn22.
tkadm30 Posted March 23, 2017 Author Posted March 23, 2017 (edited) Is aripiprazole a selective FAAH inhibitor/endocannabinoid enhancer? See: https://en.wikipedia.org/wiki/Endocannabinoid_enhancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704579/ Edited March 23, 2017 by tkadm30
tkadm30 Posted April 28, 2017 Author Posted April 28, 2017 Since the endogenous cannabinoid anandamide is a substrate of the CYP2D6 enzyme, can we assume aripiprazole is activated by anandamide biosynthesis?
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now